Antibody data
- Antibody Data
- Antigen structure
- References [32]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [1]
- Other assay [5]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-12748 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- HDJ2 Monoclonal Antibody (KA2A5.6)
- Antibody type
- Monoclonal
- Antigen
- Purifed from natural sources
- Description
- MA5-12748 targets HDJ-2/DNAJ in FACS, IF, IHC (P), IP, and WB applications and shows reactivity with Bacteria, Hamster, Human, mouse, Non-human primate, Porcine, Rabbit, and Rat samples.
- Antibody clone number
- KA2A5.6
- Concentration
- 0.2 mg/mL
Submitted references ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells.
Protein farnesylation is upregulated in Alzheimer's human brains and neuron-specific suppression of farnesyltransferase mitigates pathogenic processes in Alzheimer's model mice.
Chemogenomic screening identifies the Hsp70 co-chaperone DNAJA1 as a hub for anticancer drug resistance.
The Hsp70 co-chaperone Ydj1/HDJ2 regulates ribonucleotide reductase activity.
Uterine endoplasmic reticulum stress-unfolded protein response regulation of gestational length is caspase-3 and -7-dependent.
Bioactive metabolites from Chaetomium aureum: structure elucidation and inhibition of the Hsp90 machine chaperoning activity.
Transcriptional regulation of the human thromboxane A2 receptor gene by Wilms' tumor (WT)1 and hypermethylated in cancer (HIC) 1 in prostate and breast cancers.
Ultrasound safety with midfrequency transcranial sonothrombolysis: preliminary study on normal macaca monkey brain.
Severe hepatocellular disease in mice lacking one or both CaaX prenyltransferases.
Regulated expression of the alpha isoform of the human thromboxane A2 receptor during megakaryocyte differentiation: a coordinated role for WT1, Egr1, and Sp1.
A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.
The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells.
The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.
HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.
Heat shock protein 40/DjB1 is required for thermotolerance in early phase.
Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development.
Increased expression of p62 in expanded polyglutamine-expressing cells and its association with polyglutamine inclusions.
Oculopharyngeal muscular dystrophy-like nuclear inclusions are present in normal magnocellular neurosecretory neurons of the hypothalamus.
Overexpression of HDJ-2 protects astrocytes from ischemia-like injury and reduces redistribution of ubiquitin staining in vitro.
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Role of apical caspases and glucocorticoid-regulated genes in glucocorticoid-induced apoptosis of pre-B leukemic cells.
The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Chaperone proteins abrogate inhibition of the human papillomavirus (HPV) E1 replicative helicase by the HPV E2 protein.
CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity.
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.
Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.
Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.
Luttman JH, Hoj JP, Lin KH, Lin J, Gu JJ, Rouse C, Nichols AG, MacIver NJ, Wood KC, Pendergast AM
Cell reports 2021 Oct 26;37(4):109880
Cell reports 2021 Oct 26;37(4):109880
Protein farnesylation is upregulated in Alzheimer's human brains and neuron-specific suppression of farnesyltransferase mitigates pathogenic processes in Alzheimer's model mice.
Jeong A, Cheng S, Zhong R, Bennett DA, Bergö MO, Li L
Acta neuropathologica communications 2021 Jul 27;9(1):129
Acta neuropathologica communications 2021 Jul 27;9(1):129
Chemogenomic screening identifies the Hsp70 co-chaperone DNAJA1 as a hub for anticancer drug resistance.
Nitika, Blackman JS, Knighton LE, Takakuwa JE, Calderwood SK, Truman AW
Scientific reports 2020 Aug 14;10(1):13831
Scientific reports 2020 Aug 14;10(1):13831
The Hsp70 co-chaperone Ydj1/HDJ2 regulates ribonucleotide reductase activity.
Sluder IT, Nitika, Knighton LE, Truman AW
PLoS genetics 2018 Nov;14(11):e1007462
PLoS genetics 2018 Nov;14(11):e1007462
Uterine endoplasmic reticulum stress-unfolded protein response regulation of gestational length is caspase-3 and -7-dependent.
Kyathanahalli C, Organ K, Moreci RS, Anamthathmakula P, Hassan SS, Caritis SN, Jeyasuria P, Condon JC
Proceedings of the National Academy of Sciences of the United States of America 2015 Nov 10;112(45):14090-5
Proceedings of the National Academy of Sciences of the United States of America 2015 Nov 10;112(45):14090-5
Bioactive metabolites from Chaetomium aureum: structure elucidation and inhibition of the Hsp90 machine chaperoning activity.
Kabbaj FZ, Lu S, Faouzi Mel A, Meddah B, Proksch P, Cherrah Y, Altenbach HJ, Aly AH, Chadli A, Debbab A
Bioorganic & medicinal chemistry 2015 Jan 1;23(1):126-31
Bioorganic & medicinal chemistry 2015 Jan 1;23(1):126-31
Transcriptional regulation of the human thromboxane A2 receptor gene by Wilms' tumor (WT)1 and hypermethylated in cancer (HIC) 1 in prostate and breast cancers.
Keating GL, Reid HM, Eivers SB, Mulvaney EP, Kinsella BT
Biochimica et biophysica acta 2014 Jun;1839(6):476-92
Biochimica et biophysica acta 2014 Jun;1839(6):476-92
Ultrasound safety with midfrequency transcranial sonothrombolysis: preliminary study on normal macaca monkey brain.
Shimizu J, Fukuda T, Abe T, Ogihara M, Kubota J, Sasaki A, Azuma T, Sasaki K, Shimizu K, Oishi T, Umemura S, Furuhata H
Ultrasound in medicine & biology 2012 Jun;38(6):1040-50
Ultrasound in medicine & biology 2012 Jun;38(6):1040-50
Severe hepatocellular disease in mice lacking one or both CaaX prenyltransferases.
Yang SH, Chang SY, Tu Y, Lawson GW, Bergo MO, Fong LG, Young SG
Journal of lipid research 2012 Jan;53(1):77-86
Journal of lipid research 2012 Jan;53(1):77-86
Regulated expression of the alpha isoform of the human thromboxane A2 receptor during megakaryocyte differentiation: a coordinated role for WT1, Egr1, and Sp1.
Gannon AM, Turner EC, Reid HM, Kinsella BT
Journal of molecular biology 2009 Nov 20;394(1):29-45
Journal of molecular biology 2009 Nov 20;394(1):29-45
A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.
Coffinier C, Hudon SE, Lee R, Farber EA, Nobumori C, Miner JH, Andres DA, Spielmann HP, Hrycyna CA, Fong LG, Young SG
The Journal of biological chemistry 2008 Apr 11;283(15):9797-804
The Journal of biological chemistry 2008 Apr 11;283(15):9797-804
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.
Shachaf CM, Perez OD, Youssef S, Fan AC, Elchuri S, Goldstein MJ, Shirer AE, Sharpe O, Chen J, Mitchell DJ, Chang M, Nolan GP, Steinman L, Felsher DW
Blood 2007 Oct 1;110(7):2674-84
Blood 2007 Oct 1;110(7):2674-84
The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells.
Qiu Y, Liu X, Zou W, Yue P, Lonial S, Khuri FR, Sun SY
Cancer research 2007 May 15;67(10):4973-80
Cancer research 2007 May 15;67(10):4973-80
The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.
Sun SY, Liu X, Zou W, Yue P, Marcus AI, Khuri FR
The Journal of biological chemistry 2007 Jun 29;282(26):18800-9
The Journal of biological chemistry 2007 Jun 29;282(26):18800-9
HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.
Coffinier C, Hudon SE, Farber EA, Chang SY, Hrycyna CA, Young SG, Fong LG
Proceedings of the National Academy of Sciences of the United States of America 2007 Aug 14;104(33):13432-7
Proceedings of the National Academy of Sciences of the United States of America 2007 Aug 14;104(33):13432-7
Heat shock protein 40/DjB1 is required for thermotolerance in early phase.
Uchiyama Y, Takeda N, Mori M, Terada K
Journal of biochemistry 2006 Dec;140(6):805-12
Journal of biochemistry 2006 Dec;140(6):805-12
Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development.
Mijimolle N, Velasco J, Dubus P, Guerra C, Weinbaum CA, Casey PJ, Campuzano V, Barbacid M
Cancer cell 2005 Apr;7(4):313-24
Cancer cell 2005 Apr;7(4):313-24
Increased expression of p62 in expanded polyglutamine-expressing cells and its association with polyglutamine inclusions.
Nagaoka U, Kim K, Jana NR, Doi H, Maruyama M, Mitsui K, Oyama F, Nukina N
Journal of neurochemistry 2004 Oct;91(1):57-68
Journal of neurochemistry 2004 Oct;91(1):57-68
Oculopharyngeal muscular dystrophy-like nuclear inclusions are present in normal magnocellular neurosecretory neurons of the hypothalamus.
Berciano MT, Villagra NT, Ojeda JL, Navascues J, Gomes A, Lafarga M, Carmo-Fonseca M
Human molecular genetics 2004 Apr 15;13(8):829-38
Human molecular genetics 2004 Apr 15;13(8):829-38
Overexpression of HDJ-2 protects astrocytes from ischemia-like injury and reduces redistribution of ubiquitin staining in vitro.
Qiao Y, Ouyang YB, Giffard RG
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2003 Oct;23(10):1113-6
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2003 Oct;23(10):1113-6
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Patnaik A, Eckhardt SG, Izbicka E, Tolcher AA, Hammond LA, Takimoto CH, Schwartz G, McCreery H, Goetz A, Mori M, Terada K, Gentner L, Rybak ME, Richards H, Zhang S, Rowinsky EK
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Oct 15;9(13):4761-71
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Oct 15;9(13):4761-71
Role of apical caspases and glucocorticoid-regulated genes in glucocorticoid-induced apoptosis of pre-B leukemic cells.
Planey SL, Abrams MT, Robertson NM, Litwack G
Cancer research 2003 Jan 1;63(1):172-8
Cancer research 2003 Jan 1;63(1):172-8
The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.
Delmas C, End D, Rochaix P, Favre G, Toulas C, Cohen-Jonathan E
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Dec 1;9(16 Pt 1):6062-8
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Dec 1;9(16 Pt 1):6062-8
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003 Apr 1;21(7):1301-6
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003 Apr 1;21(7):1301-6
Chaperone proteins abrogate inhibition of the human papillomavirus (HPV) E1 replicative helicase by the HPV E2 protein.
Lin BY, Makhov AM, Griffith JD, Broker TR, Chow LT
Molecular and cellular biology 2002 Sep;22(18):6592-604
Molecular and cellular biology 2002 Sep;22(18):6592-604
CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity.
Imai Y, Soda M, Hatakeyama S, Akagi T, Hashikawa T, Nakayama KI, Takahashi R
Molecular cell 2002 Jul;10(1):55-67
Molecular cell 2002 Jul;10(1):55-67
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Peters DG, Hoover RR, Gerlach MJ, Koh EY, Zhang H, Choe K, Kirschmeier P, Bishop WR, Daley GQ
Blood 2001 Mar 1;97(5):1404-12
Blood 2001 Mar 1;97(5):1404-12
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Peters DG, Hoover RR, Gerlach MJ, Koh EY, Zhang H, Choe K, Kirschmeier P, Bishop WR, Daley GQ
Blood 2001 Mar 1;97(5):1404-12
Blood 2001 Mar 1;97(5):1404-12
A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.
Britten CD, Rowinsky EK, Soignet S, Patnaik A, Yao SL, Deutsch P, Lee Y, Lobell RB, Mazina KE, McCreery H, Pezzuli S, Spriggs D
Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Dec;7(12):3894-903
Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Dec;7(12):3894-903
Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE
Cancer research 2001 Dec 15;61(24):8758-68
Cancer research 2001 Dec 15;61(24):8758-68
Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.
Wyttenbach A, Swartz J, Kita H, Thykjaer T, Carmichael J, Bradley J, Brown R, Maxwell M, Schapira A, Orntoft TF, Kato K, Rubinsztein DC
Human molecular genetics 2001 Aug 15;10(17):1829-45
Human molecular genetics 2001 Aug 15;10(17):1829-45
Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.
Wyttenbach A, Swartz J, Kita H, Thykjaer T, Carmichael J, Bradley J, Brown R, Maxwell M, Schapira A, Orntoft TF, Kato K, Rubinsztein DC
Human molecular genetics 2001 Aug 15;10(17):1829-45
Human molecular genetics 2001 Aug 15;10(17):1829-45
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot of HDJ-2/DNAJ using HDJ-2/DNAJ Monoclonal Antibody (Product # MA5-12748) on MAD109 Cells.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis was performed on whole cell extracts (30 µg lysate) of NTERA-2 (Lane 1), HeLa (Lane 2), A-431 (Lane 3), A549 (Lane 4), PC-3 (Lane 5), and Jurkat (Lane 6). The blots were probed with Anti-SNRPB Monoclonal Antibody (Product # MA5-12748, 1 µg/mL) and detected by chemiluminescence using Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A28177, 0.25 µg/mL, 1:4000 dilution). A 45 kDa corresponding to HDJ2 was observed across the cell lines tested. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 4-12 % Bis-Tris gel (Product # NP0321BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane with iBlot® 2 Dry Blotting System (Product # IB21001). The membrane was probed with the relevant primary and secondary antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Formalin-fixed, paraffin-embedded human tonsil stained with HDJ-2 antibody using peroxidase-conjugate and AEC chromogen. Note cytoplasmic staining of cells.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoprecipitation of HDJ2 using a monoclonal antibody (Product # MA5-12748).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoprecipitation of HDJ2 using a monoclonal antibody (Product # MA5-12748).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoprecipitation of HDJ2 using a monoclonal antibody (Product # MA5-12748).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 3 Generation of forebrain neuron-specific FT knockout mice. A Schematic representation of the 3-step breeding strategy to generate APP/PS1 mice harboring homozygous FT knockout in forebrain neurons (APP/PS1/FTnKO) and littermate controls. B Representative immunoblot images of FT-beta and HDJ-2, a well-known farnesylated protein that is widely used as a marker for farnesylation, in cortical, hippocampal, cerebellar tissue homogenates of WT and FTnKO mice at 3 and 6 months of age. Unfarnesylated HDJ-2 band is detected in the forebrain region (cortex and hippocampus), but not in the cerebellum, of FTnKO mice at 3 months, and the level is elevated at 6 months, confirming both brain region- and age-dependent deletion of FT. C , D Immunoblot analysis of representative small GTPases in membrane (M) and cytosolic (C) fractions of cortical tissue lysates of FTnKO mice compared with WT controls (n = 5/genotype). Membrane-associated FT substrates, farnesylated H-Ras and Rheb, are reduced significantly or trending reduction in FTnKO compared with WT controls, whereas membrane levels of GGT substrate RhoA are not affected, confirming the specificity of FT deletion. E Representative immunoblot images of HDJ-2 in cortical tissue homogenates of APP/PS1 and APP/PS1/FTnKO mice at 9-10 months of age. F , G Immunoblot analysis of representative small GTPases in membrane (M) and cytosolic (C) fractions of cortical tissue lysates from APP/PS1 and APP/PS1/FTnKO mice at 9-10 months of age (n =
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5. Apoptotic sensitization to statin therapy by ABL allosteric inhibitors requires inhibition of protein prenylation (A) Cell viability of PC9 GR4 cells treated singly or with the combination of 5 muM ABL001 and 1 muM simvastatin supplemented with 500 muM MVA, 10 muM FPP, or 10 muM GGPP for 72 h (n = 3). Data are the mean +- SEM. (B) Immunoblots of unprenylated RAP1A, HDJ-2, and beta-tubulin in PC9 GR4 cells treated for 24 h with 5 muM ABL001 and 1 muM simvastatin supplemented with 500 muM MVA, 10 muM FPP (farnesylation metabolite), or 10 muM GGPP (geranylgeranylation metabolite). Simvastatin caused a mobility shift of HDJ-2 (slower, migrating unprenylated form) and induced the appearance of unprenylated RAP1A. Prenylation alterations were rescued with the indicated metabolites for each pathway (n = 3). (C) Cell viability of PC9 GR4 cells treated with 5 muM ABL001 and 1 muM simvastatin, 500 muM MVA, 5 muM GGTI-298 (GGT inhibitor), and 12.5 muM FTI-277 (FT inhibitor) for 72 h (n = 3). Data are the mean +- SEM. (D) Immunoblots of unprenylated RAP1A, HDJ-2, and beta-tubulin in PC9 GR4 cells treated for 24 h with 5 muM ABL001 and 1 muM simvastatin supplemented with 500 muM MVA, 5 muM GGTI-298, and 12.5 muM FTI-277 (n = 3). (E) Mitochondrial basal respiration, maximal respiration, and ATP production as measured by Seahorse XF Analyzer's Mito Stress Test for PC9 GR4 cells treated singly or with indicated combinations of 2.5 muM ABL001, 1 muM simvastatin, 500 muM MVA, 5 muM G